Key Laboratory for Regenerative Medicine; Ministry of Education; School of Biomedical Sciences; Faculty of Medicine; The Chinese University of Hong Kong; Hong Kong, P.R. China.
Epigenetics. 2014 Jan;9(1):119-28. doi: 10.4161/epi.25799. Epub 2013 Aug 19.
It was previously demonstrated that miR-199a was downregulated in testicular germ cell tumor (TGCT), probably due to hypermethylation of its promoter. Further study found that re-expression of miR-199a in testicular cancer cells (NT2) led to suppression of cell growth, cancer migration, invasion and metastasis. More detailed analyses showed that these properties of miR-199a could be assigned to miR-199a-5p, one of its two derivatives. The biological role of the other derivative, miR-199a-3p in TGCT, remains largely uncharacterized. In this report, we identified DNA (cytosine-5)-methyltransferase 3A (DNMT3A), the de novo methyltransferase, as a direct target of miR-199a-3p using a 3'-UTR reporter assay. Transient expression of miR-199a-3p in NT2 cells led to decrease, while knocking down of miR-199a-3p in a normal human testicular cell line (HT) led to elevation, of DNMT3A2 (DNMT3A gene isoform 2) mRNA and protein levels. In clinical samples, DNMT3A2 was significantly overexpressed in malignant testicular tumor, and the expression of DNMT3A2 was inversely correlated with the expression of miR-199a-3p. However, DNMT3A did not affect miR-199a expression in NT2 cells. Further characterization of miR-199a-3p revealed that it negatively regulated DNA methylation, partly through targeting DNMT3A. Overexpression of miR-199a-3p restored the expression of APC and MGMT tumor-suppressor genes in NT2 cells by affecting DNA methylation of their promoter regions. Our studies demonstrated the deregulation of miR-199a-3p expression in TGCT may provide novel mechanistic insights into TGCT carcinogenesis and suggested a potentially therapeutic use of synthetic miR-199a-3p oligonucleotides as effective hypomethylating compounds in the treatment of TGCT.
先前的研究表明,miR-199a 在睾丸生殖细胞瘤 (TGCT) 中表达下调,可能是由于其启动子的超甲基化。进一步的研究发现,miR-199a 在睾丸癌细胞 (NT2) 中的重新表达导致细胞生长、癌症迁移、侵袭和转移的抑制。更详细的分析表明,miR-199a 的这些特性可以归因于其两个衍生物之一的 miR-199a-5p。其另一个衍生物 miR-199a-3p 在 TGCT 中的生物学作用在很大程度上仍未被描述。在本报告中,我们使用 3'-UTR 报告基因检测鉴定了从头甲基转移酶 DNA(cytosine-5)-甲基转移酶 3A (DNMT3A) 作为 miR-199a-3p 的直接靶标。miR-199a-3p 在 NT2 细胞中的瞬时表达导致 DNMT3A2 (DNMT3A 基因 2 型) mRNA 和蛋白水平降低,而在正常人类睾丸细胞系 (HT) 中敲低 miR-199a-3p 则导致 DNMT3A2 升高。在临床样本中,DNMT3A2 在恶性睾丸肿瘤中显著过表达,并且 DNMT3A2 的表达与 miR-199a-3p 的表达呈负相关。然而,DNMT3A 不会影响 NT2 细胞中 miR-199a 的表达。对 miR-199a-3p 的进一步表征表明,它通过靶向 DNMT3A 负调控 DNA 甲基化。miR-199a-3p 的过表达通过影响其启动子区域的 DNA 甲基化,在 NT2 细胞中恢复 APC 和 MGMT 肿瘤抑制基因的表达。我们的研究表明,miR-199a-3p 在 TGCT 中的表达失调可能为 TGCT 致癌机制提供新的见解,并表明合成 miR-199a-3p 寡核苷酸作为治疗 TGCT 的有效去甲基化化合物具有潜在的治疗用途。